Target Groups Get Pfizer-BioNTech, Oxford-AstraZeneca Vaccines
Category: Coronavirus
target-groups-get-pfizer-biontech,-oxford-astrazeneca-vaccines_kuwait

The Ministry of Health is giving Pfizer-BioNTech and Oxford-AstraZeneca, the two vaccines against coronavirus (Covid-19), to the target segments.

As many as 14,463 people took Oxford-AstraZeneca, covering 20 percent of the target segment for this vaccine as part of the first dose.
The vaccine is being administered to people aged 65 and above, irrespective of whether or not they are healthy or suffer from any chronic disease.

Meanwhile, about 27,000 people were vaccinated with Pfizer-BioNTech, constituting 95 percent of the target segment (first dose) while the second dose was administered to 22,369 people, 82 percent of the target group.

The Ministry of Health reaffirmed its drive to receive more stocks of the vaccines through accredited channels and to achieve its objectives based on established methods devised by the specialised team, with emphasis on safety, validity and speed of supply of the vaccines after obtaining approval from national and international agencies and organisations.

A number of agreements were signed to this effect by the Government of the Sultanate and international Covid-19 vaccine producing firms and Global Alliance for Vaccines and Immunisation (GAVI).

The number of doses that arrived at the Sultanate so far stood at 156,000, of which 56,000 were of Pfizer-BioNTech and 100,000 doses of Oxford-AstraZeneca.

Meanwhile, the total number of positive Covid-19 cases in the Sultanate reached 138,206 while the number of recoveries stood at 1297,52, comprising 94 percent.

The total number of Covid-19 related death cases stood at 1,549, the Ministry of Health said.

The Ministry also pointed out that 27 cases were hospitalised over the past 24 hours, adding that the total number of current hospitalized Covid-19-infected patients stands at 147, of them 46 are in intensive care units (ICU).
 

SOURCE: TIMESOFOMAN

18 Feb, 2021 0 236
Posted Comments